BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL treatment but is associated with adverse cardiovascular events such as atrial fibrillation (AF) and hypertension (HTN).